Becton, Dickinson and Company (BDX) to Issue Quarterly Dividend of $1.05 on June 30th

Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Tuesday, April 28th. Shareholders of record on Tuesday, June 9th will be paid a dividend of 1.05 per share by the medical instruments supplier on Tuesday, June 30th. This represents a c) annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Tuesday, June 9th.

Becton, Dickinson and Company has increased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 53 consecutive years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Becton, Dickinson and Company to earn $13.76 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 30.5%.

Becton, Dickinson and Company Stock Up 1.2%

Shares of NYSE:BDX opened at $151.33 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The business has a 50 day simple moving average of $150.72 and a two-hundred day simple moving average of $175.54. The firm has a market capitalization of $41.70 billion, a PE ratio of 38.31, a price-to-earnings-growth ratio of 10.70 and a beta of 0.22. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the previous year, the business earned $3.35 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current year.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.